Deciphera’s oncology drugs arrest cancer-causing kinases into inactive forms, preventing or reversing tumor progression. The Switch Pocket mechanism of these drugs enables durable kinase inhibition even in the face of kinase mutations that cause resistance to other types of kinase inhibitors. These attributes provide patients with more durable kinase blocking therapies. These agents also exhibit high selectivity profiles, enabling the inhibition of specific cancer-causing kinases without affecting the function of a host of other kinases required for normal health.
Deciphera's oncology drugs not only directly block tumor growth and invasiveness, but they also block communication of tumors with the surrounding tissue, called the tumor microenvironment. This dual mechanism provides a novel way of blocking tumor invasiveness and metastasis.
To learn additional information, please select a drug candidate below.